On May 15,
a Wall Street Journal article highlighted middle market investment bank Leerink Swann's of immuno-oncology addressable market as an annual $20 billion figure. A week later,
Citigroup analyst Andrew Baum was quoted by Reuters sizing the market as $35 billion a year over the next 10 years for, where this category of drugs would be used in some way in the management of up to 60% of all cancers. I think the immuno-oncology category includes immuntherapies broadly, but it's possible the above estimates are inclusive only of anti-CTLA-4, anti-PD1 and anti-PDL-1 (and the like) agents.
No comments:
Post a Comment